Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kala Pharmaceuticals Q1 EPS $(6.99) Misses $(5.68) Estimate; Cash & Cash Equivalents Of $63.6M With Anticipated Funding Under The CIRM Award, Will Enable It To Fund Operations Into Q1 Of 2025

Author: Benzinga Newsdesk | May 09, 2023 08:08am
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(6.99) per share which missed the analyst consensus estimate of $(5.68) by 23.06 percent. This is a 68.49 percent increase over losses of $(22.18) per share from the same period last year.

Posted In: KALA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist